Avoided recurrences and costs with adjuvant atezolizumab for patients with early non-small cell lung cancer in Europe
Adjuvant atezolizumab may provide a meaningful reduction in recurrences and associated treatment costs among patients with early non-small cell lung cancer in Europe.
Authors
- Pavel Napalkov
- Alastair Greystoke (ORCID: https://orcid.org/0000-0001-9168-0387)
- Nick Jovanoski
- Melina Arnold (ORCID: https://orcid.org/0000-0003-1700-6831)
Institutions
- Roche (Switzerland) (CH)
- ACCESS Health International (US)
- Newcastle University (GB)
Publication Details
- Journal
- Immunotherapy
- Published
- 2024-10-27
- DOI
- https://doi.org/10.1080/1750743x.2024.2429958
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- F. Hoffmann-La Roche
- Flatiron Health